Medpace (MEDP) stock dips while market gains: Key facts

Medpace (MEDP – Free Report) ended the recent trading session at $600.02, demonstrating a -2.13% change from the preceding day’s closing price. This move lagged the S&P 500’s daily gain of 0.01%. At the same time, the Dow added 0.55%, and the tech-heavy Nasdaq lost 0.44%.

Prior to today’s trading, shares of the provider of outsourced clinical development services had gained 9.33% outpaced the Medical sector’s gain of 2.01% and the S&P 500’s gain of 0.86%.

Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. The company’s earnings report is set to be unveiled on February 9, 2026. On that day, Medpace is projected to report earnings of $4.18 per share, which would represent year-over-year growth of 13.9%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $681.17 million, up 26.94% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $14.8 per share and revenue of $2.5 billion, indicating changes of +17.18% and 0%, respectively, compared to the previous year.

Investors should also take note of any recent adjustments to analyst estimates for Medpace. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts’ positivity towards the business operations and its ability to generate profits.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we’ve crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there’s been no change in the Zacks Consensus EPS estimate. As of now, Medpace holds a Zacks Rank of #2 (Buy).

Looking at its valuation, Medpace is holding a Forward P/E ratio of 36.88. This expresses a premium compared to the average Forward P/E of 15.62 of its industry.

Also, we should mention that MEDP has a PEG ratio of 2.06. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock’s expected earnings growth rate. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.89.

The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 175, which puts it in the bottom 29% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don’t forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.